Guidance includes a negative currency impact for Q1 of approximately $1.3M versus prior year. PDN indication sales in the first quarter of 2023 are expected to be approximately 15% to 20% below 4Q22 and then expected to grow sequentially each quarter for the remainder of 2023 given the underlying strong momentum in this indication. Expects Q1 non-GAAP adjusted EBITDA to be a loss of approximately $19M-$20M.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NVRO:
- Nevro Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides First Quarter and Complete Full-Year 2023 Guidance
- Nevro price target raised to $72 from $67 at Canaccord
- Abbott approval ‘incremental headwind’ to Nevro, says Piper Sandler
- Nevro price target lowered to $37 from $38 at Piper Sandler
- Nevro downgraded to Neutral from Buy at Citi
